Base de dados : MEDLINE
Pesquisa : C18.452.584.500 [Categoria DeCS]
Referências encontradas : 8896 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 890 ir para página                         

  1 / 8896 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29397593
[Au] Autor:Committee of Cardio-Cerebro-Vascular Diseases of Gerontological Society of China; Working Group of Chinese Expert Consensus on the Use of Xuezhikang
[Ti] Título:[Chinese expert consensus on the use of Xuezhikang (2017 revised edition)].
[So] Source:Zhonghua Nei Ke Za Zhi;57(2):97-100, 2018 Feb 01.
[Is] ISSN:0578-1426
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:Xuezhikang, a Chinese traditional medicine, contains natural statin and is effective on dyslipidemia by inhibiting cholesterol synthesis. Xuezhikang therapy for 8 weeks in patients with hyperlipidemia reduced total cholesterol (TC) by 23%, low density lipoprotein cholesterol (LDL-C) by 28.5% and triglyceride(TG) by 36.5%, and increased high density lipoprotein cholesterol (HDL-C) by 19.6%, respectively. Data from China Coronary Secondary Prevention Study (CCSPS) showed that treatment with Xuezhikang lowered the risks of major coronary events, death from coronary heart disease, and all cause death in patients with myocardial infarction, indicating that Xuezhikang can be used in the primary and secondary prevention of cardiovascular disease.
[Mh] Termos MeSH primário: Consenso
Medicamentos de Ervas Chinesas/uso terapêutico
Dislipidemias/tratamento farmacológico
Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico
[Mh] Termos MeSH secundário: Grupo com Ancestrais do Continente Asiático
Causas de Morte
China
LDL-Colesterol
Seres Humanos
Infarto do Miocárdio
Prevenção Secundária
Triglicerídeos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cholesterol, LDL); 0 (Drugs, Chinese Herbal); 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors); 0 (Triglycerides); 0 (xuezhikang)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180306
[Lr] Data última revisão:
180306
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180206
[St] Status:MEDLINE
[do] DOI:10.3760/cma.j.issn.0578-1426.2018.02.003


  2 / 8896 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29303009
[Au] Autor:Katsiki N; Kolovou G; Perez-Martinez P; Mikhailidis DP
[Ad] Endereço:a Second Propedeutic Department of Internal Medicine, Medical School , Aristotle University of Thessaloniki, Hippocration Hospital , Thessaloniki , Greece.
[Ti] Título:Dyslipidaemia in the elderly: to treat or not to treat?
[So] Source:Expert Rev Clin Pharmacol;11(3):259-278, 2018 Mar.
[Is] ISSN:1751-2441
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: The elderly population (i.e. aged ≥ 65 years) is increasing worldwide. Ageing is associated with a higher incidence and prevalence of cardiovascular disease (CVD). Areas covered: The prevalence of CVD risk factors including type 2 diabetes mellitus, hypertension and dyslipidaemia also increases with advancing age, contributing to the higher absolute CVD risk observed in the elderly. The present narrative review comments on the associations of dyslipidaemia with CVD as well as the effects of lifestyle measures and lipid-lowering drugs on lipids and CVD risk with a special focus on the elderly population. Individual treatment goals and therapeutic options according to current guidelines are also reviewed. Finally, we discuss special characteristics of the elderly that may influence the efficacy and safety of drug therapy and should be considered before selection of hypolipidaemic pharmacotherapy. Expert commentary: There may be a greater CVD benefit in older patients following drug therapy compared with younger ones. Treatment goals and therapeutic options should be individualized according to current guidelines. Specific characteristics that may influence the efficacy and safety of drug therapy in the elderly should be considered in relation to dyslipidaemia treatment.
[Mh] Termos MeSH primário: Doenças Cardiovasculares/prevenção & controle
Dislipidemias/tratamento farmacológico
Hipolipemiantes/uso terapêutico
[Mh] Termos MeSH secundário: Fatores Etários
Idoso
Doenças Cardiovasculares/etiologia
Dislipidemias/complicações
Dislipidemias/epidemiologia
Seres Humanos
Hipolipemiantes/efeitos adversos
Incidência
Estilo de Vida
Guias de Prática Clínica como Assunto
Prevalência
Fatores de Risco
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Hypolipidemic Agents)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180106
[St] Status:MEDLINE
[do] DOI:10.1080/17512433.2018.1425138


  3 / 8896 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29428127
[Au] Autor:Liao J; Liu X; Gao M; Wang M; Wang Y; Wang F; Huang W; Liu G
[Ad] Endereço:Department of Cardiology, Institute of Cardiovascular Diseases, First Affiliated Hospital of Dalian Medical University, Dalian 116011, China; Institute of Cardiovascular Sciences and Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education, Peking University Health Science Center,
[Ti] Título:Dyslipidemia, steatohepatitis and atherogenesis in lipodystrophic apoE deficient mice with Seipin deletion.
[So] Source:Gene;648:82-88, 2018 Mar 30.
[Is] ISSN:1879-0038
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:SEIPIN is an integral membrane protein located in the endoplasmic reticulum, regulating adipocytes differentiation and lipolysis. Deficiency of Seipin in mice causes severe general lipodystrophy, accompanied by insulin resistance, postprandial hypertriglyceridemia and steatohepatitis. In atherosclerosis-prone Ldlr null (Ldlr ) mice, lipodystrophy caused by Seipin deletion even led to severe hypercholesteremia and accelerated atherogenesis, when challenged with an atherogenic diet. However, whether the phenotypes observed in Seipin Ldlr mice were a common consequence due to lipodystrophy, rather than genetic background restricted or diet dependent, was unknown. Herein we explored the lipodystrophy-related dyslipidemia, steatohepatitis and atherogenesis in another atherosclerosis-prone murine model, apolipoprotein E null (apoE ) mice. Besides, we also compared phenotypes between sexes in apoE mice with Seipin deletion (Seipin apoE ). We found that compared with apoE controls, Seipin apoE mice also developed severe general lipodystrophy with hyperlipidemia, steatohepatitis and increased atherogenesis. Although the severity of adipose loss in female and male Seipin apoE mice were similar, hyperlipidemia, steatohepatitis and atherosclerosis were less severe in females than in males. Therefore, we demonstrated that lipodystrophy-related metabolic disorders, caused by Seipin deletion, were independent of genetic background and experimental diet, as seen in Ldlr and apoE mice. However, gender factor affected the disease progression, with females more resistant to developing lipodystrophy-related metabolic consequences.
[Mh] Termos MeSH primário: Apolipoproteínas E/genética
Aterosclerose/genética
Dislipidemias/genética
Fígado Gorduroso/genética
Proteínas Heterotriméricas de Ligação ao GTP/genética
Lipodistrofia/genética
[Mh] Termos MeSH secundário: Animais
Apolipoproteínas E/deficiência
Aterosclerose/metabolismo
Aterosclerose/patologia
Progressão da Doença
Dislipidemias/metabolismo
Dislipidemias/patologia
Fígado Gorduroso/metabolismo
Fígado Gorduroso/patologia
Feminino
Proteínas Heterotriméricas de Ligação ao GTP/deficiência
Lipodistrofia/metabolismo
Lipodistrofia/patologia
Masculino
Camundongos Endogâmicos C57BL
Camundongos Knockout
Receptores de LDL/deficiência
Receptores de LDL/genética
Índice de Gravidade de Doença
Fatores Sexuais
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Apolipoproteins E); 0 (Bscl2 protein, mouse); 0 (Receptors, LDL); EC 3.6.5.1 (Heterotrimeric GTP-Binding Proteins)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180212
[St] Status:MEDLINE


  4 / 8896 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29352300
[Au] Autor:Wang Z; Koonen D; Hofker M; Bao Z
[Ad] Endereço:Department of Geriatrics and Gastroenterology, Huadong Hospital, Shanghai Medical College, Fudan University, Shanghai Key Laboratory of Clinical Geriatric Medicine, Shanghai, P.R. China.
[Ti] Título:5-aminosalicylic acid improves lipid profile in mice fed a high-fat cholesterol diet through its dual effects on intestinal PPARγ and PPARα.
[So] Source:PLoS One;13(1):e0191485, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Obesity is associated with a series of metabolic complications, including dyslipidemia and insulin resistance (IR) that lack effective therapies. In recent years, intestinal inflammation has been suggested to contribute to obesity related metabolic syndrome and targeting gut inflammation with 5-ASA improves diet induced IR, however, its role in dyslipidemia is unknown and has never been explored. In the present study, we reported for the first time that administration of 5-ASA for 12 weeks significantly improved lipid profile by repressing plasma triglycerides and free cholesterol levels in mice fed high-fat cholesterol diet (HFC). In addition, liver lipids were significantly reduced by 5-ASA treatment in HFC-fed mice. Mechanistically, anti-inflammatory genes peroxisome proliferator-activated receptor-γ (Pparγ) and M2 marker, such as Mrc1 and Ym1, were remarkably upregulated, while pro-inflammation gene monocyte chemoattractant protein-1 (Mcp-1) were downregulated in small intestine of mice treated by 5-ASA. Further, 5-ASA improved gastrointestinal barrier by increasing the expression of the tight junction marker ZO-1. 5-ASA also enhanced cholesterol translocation by elevating genes expression of Npc1l1 and Abcg5/8. Moreover, mice fed HFC 5-ASA expressed increased Pparα in small intestinal and its target genes function in lipid oxidation and hydrolysis were remarkable elevated. Taken together, we reported a novel role of 5-ASA which may serve as a therapy target intestinal inflammation induced dyslipidemia.
[Mh] Termos MeSH primário: Colesterol na Dieta/administração & dosagem
Dieta Hiperlipídica/efeitos adversos
Intestinos/efeitos dos fármacos
Intestinos/metabolismo
Metabolismo dos Lipídeos/efeitos dos fármacos
Mesalamina/farmacologia
PPAR alfa/metabolismo
PPAR gama/metabolismo
[Mh] Termos MeSH secundário: Animais
Anti-Inflamatórios não Esteroides/farmacologia
Dislipidemias/tratamento farmacológico
Dislipidemias/genética
Dislipidemias/metabolismo
Ácidos Graxos/metabolismo
Hipolipemiantes/farmacologia
Inflamação/tratamento farmacológico
Inflamação/genética
Inflamação/metabolismo
Metabolismo dos Lipídeos/genética
Lipídeos/sangue
Fígado/efeitos dos fármacos
Fígado/metabolismo
Masculino
Camundongos
Camundongos Endogâmicos C57BL
PPAR gama/genética
RNA Mensageiro/genética
RNA Mensageiro/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents, Non-Steroidal); 0 (Cholesterol, Dietary); 0 (Fatty Acids); 0 (Hypolipidemic Agents); 0 (Lipids); 0 (PPAR alpha); 0 (PPAR gamma); 0 (RNA, Messenger); 4Q81I59GXC (Mesalamine)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180121
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0191485


  5 / 8896 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28469108
[Au] Autor:Pérez-Hernández N; Aptilon-Duque G; Blachman-Braun R; Vargas-Alarcón G; Rodríguez-Cortés AA; Azrad-Daniel S; Posadas-Sánchez R; Rodríguez-Pérez JM
[Ad] Endereço:Department of Molecular Biology, National Institute of Cardiology "Ignacio Chávez", México, Mexico City 14080, México.
[Ti] Título:Vascular Calcification: Current Genetics Underlying This Complex Phenomenon.
[So] Source:Chin Med J (Engl);130(9):1113-1121, 2017 May 05.
[Is] ISSN:0366-6999
[Cp] País de publicação:China
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Vascular calcification is the consequence of the complex interaction between genetic, environmental, and vascular factors, which ultimately lead to the deposition of calcium in the tunica intima (atherosclerotic calcification) or tunica media (Mönckenberg's sclerosis). Vascular calcification is also closely related to other pathologies, such as diabetes mellitus, dyslipidemia, and chronic kidney disease. It has been concluded that the degree of vascular calcification may vary from person to person, even if the associated pathologies and environmental factors are the same. Therefore, this suggests an important genetic contribution to the development of vascular calcification. This review aimed to find the most recent evidence about vascular calcification pathophysiology regarding the genetic aspects and molecular pathways. DATA SOURCES: We conducted an exhaustive search in Scopus, EBSCO, and PubMed with the keywords "genetics and vascular calcification", "molecular pathways, genetic and vascular calcification" and included the main articles from January 1995 up to August 2016. We focused on the most recent evidence about vascular calcification pathophysiology regarding the genetic aspects and molecular pathways. STUDY SELECTION: The most valuable published original and review articles related to our objective were selected. RESULTS: Vascular calcification is a multifactorial disease; thus, its pathophysiology cannot be explained by a single specific factor, rather than by the result of the association of several genetic variants, molecular pathway interactions, and environmental factors that promote its development. CONCLUSION: Although several molecular aspects of this mechanism have been elucidated, there is still a need for a better understanding of the factors that predispose to this disease.
[Mh] Termos MeSH primário: Calcificação Vascular/metabolismo
Calcificação Vascular/fisiopatologia
[Mh] Termos MeSH secundário: Diabetes Mellitus/metabolismo
Diabetes Mellitus/fisiopatologia
Dislipidemias/metabolismo
Dislipidemias/fisiopatologia
Seres Humanos
Falência Renal Crônica/metabolismo
Falência Renal Crônica/fisiopatologia
Insuficiência Renal Crônica/metabolismo
Insuficiência Renal Crônica/fisiopatologia
Túnica Íntima/metabolismo
Túnica Íntima/fisiopatologia
Túnica Média/metabolismo
Túnica Média/fisiopatologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170505
[St] Status:MEDLINE
[do] DOI:10.4103/0366-6999.204931


  6 / 8896 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Texto completo
[PMID]:28454530
[Au] Autor:Nielsen TRH; Lausten-Thomsen U; Fonvig CE; Bøjsøe C; Pedersen L; Bratholm PS; Hansen T; Pedersen O; Holm JC
[Ad] Endereço:The Children's Obesity Clinic, Department of Pediatrics, Copenhagen University Hospital Holbæk, Smedelundsgade 60, DK 4300, Holbæk, Denmark. ter@regionsjaelland.dk.
[Ti] Título:Dyslipidemia and reference values for fasting plasma lipid concentrations in Danish/North-European White children and adolescents.
[So] Source:BMC Pediatr;17(1):116, 2017 Apr 28.
[Is] ISSN:1471-2431
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Dyslipidemia is reported in 27 - 43% of children and adolescents with overweight/obesity and tracks into adulthood, increasing the risk of cardiovascular morbidity. Cut-off values for fasting plasma lipid concentrations are typically set at fixed levels throughout childhood. The objective of this cross-sectional study was to generate fasting plasma lipid references for a Danish/North-European White population-based cohort of children and adolescents, and investigate the prevalence of dyslipidemia in this cohort as well as in a cohort with overweight/obesity. METHODS: A population-based cohort of 2141 (1275 girls) children and adolescents aged 6 - 19 (median 11.5) years was recruited from 11 municipalities in Denmark. Additionally, a cohort of children and adolescents of 1421 (774 girls) with overweight/obesity aged 6 - 19 years (median 11.8) was recruited for the study. Height, weight, and fasting plasma lipid concentrations were measured on all participants. Smoothed reference curves and percentiles were generated using the Generalized Additive Models for Location Scale and Shape package in the statistical software R. RESULTS: In the population-based cohort, plasma concentrations of total cholesterol (TC) (P < 0.05), low-density lipoprotein cholesterol (LDL) (P < 0.005), and high-density lipoprotein cholesterol (HDL) (P < 0.005) were higher in the youngest compared to the oldest tertile. Fasting plasma levels of triglycerides (TG) (P < 0.005) increased with age in both sexes. In boys, non-HDL was lower in the oldest compared to the youngest tertile (P < 0.0005). Concentrations of TC, LDL, non-HDL, and TG were higher (P < 0.05), and HDL lower (P < 0.05) in the cohort with overweight/obesity in both sexes and for all ages except for TC in the youngest girls. The overall prevalence of dyslipidemia was 6.4% in the population-based cohort and 28.0% in the cohort with overweight/obesity. The odds ratio for exhibiting dyslipidemia in the cohort with overweight/obesity compared with the population-based cohort was 6.2 (95% CI: 4.9 - 8.1, P < 2*10 ). CONCLUSION: Fasting plasma lipid concentrations change during childhood and adolescence and differ with sex and age. Children and adolescents with obesity have increased concentrations of circulating lipids and exhibit an increased prevalence of dyslipidemia. TRIAL REGISTRATION: The study is part of The Danish Childhood Obesity Biobank; ClinicalTrials.gov ID-no.: NCT00928473 retrospectively registered on June 25th 2009.
[Mh] Termos MeSH primário: Colesterol/sangue
Dislipidemias/diagnóstico
Triglicerídeos/sangue
[Mh] Termos MeSH secundário: Adolescente
Biomarcadores/sangue
Estudos de Casos e Controles
Criança
Estudos Transversais
Dinamarca/epidemiologia
Dislipidemias/sangue
Dislipidemias/complicações
Dislipidemias/epidemiologia
Europa (Continente)/epidemiologia
Grupo com Ancestrais do Continente Europeu
Jejum
Feminino
Seres Humanos
Modelos Logísticos
Masculino
Obesidade Pediátrica/sangue
Obesidade Pediátrica/complicações
Obesidade Pediátrica/diagnóstico
Obesidade Pediátrica/epidemiologia
Prevalência
Valores de Referência
Adulto Jovem
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); 0 (Triglycerides); 97C5T2UQ7J (Cholesterol)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180223
[Lr] Data última revisão:
180223
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170430
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE
[do] DOI:10.1186/s12887-017-0868-y


  7 / 8896 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29378100
[Au] Autor:Vengerovsky AI; Yakimova TV; Nasanova ON
[Ti] Título:[The influence of nettle and burdock extracts in combination with different diets on dyslipidemia in diabetes mellitus model].
[So] Source:Vopr Pitan;84(6):69-75, 2015.
[Is] ISSN:0042-8833
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:The influence of low-fat diet, nettle (Urtica dioica) leafs and burdock (Arctium lappa) roots extracts on lipid metabolism and glycosylation reactions has been investigated in experimental diabetes mellitus. These extracts were applied in diets with both high and low fat content. The experiments were performed on 90 noninbred male albino rats (200­220 g) that were divided into 9 experimental groups. Diabetes mellitus was modeled with twice-repeated intraperitoneal streptozotocin (30 mg/kg) injections. The animals received food with increased fat content (proteins ­ 8%, fats ­ 30%, carbohydrates ­ 62% of total daily caloric content) during 4 weeks before streptozotocine injections and 8 weeks after its discontinuation. Simultaneously the rats were daily administered nettle leafs (100 mg/kg), burdock roots (25 mg/kg) extracts or metformin (100 mg/kg) into the stomach during 10 days. During the period of agents introduction half the animals continued to receive food with high fat content, the other half received low fat diet (proteins ­ 20%, fats ­ 8%, carbohydrates ­ 72% of the total daily caloric content). The forth (control) group received low fat food only without extracts or metformin administration. The levels of blood glucose, glycosylated hemoglobin, malonic dialdehyde, lipid and lipoprotein fractions content were measured. It has been shown that after streptozotocine injections and 30% fat diet consumption the blood glucose level increased by 5.3 fold compared to that of the intact animals, the content of atherogenic lipid fractions increased by 2­8.3 fold and the protein glycosylation reactions were intensified by 1.9­2.5 fold. In animals fed with 8% fat diet the blood glucose and malonic dialdehyde content decreased by 1.8­2.3 fold. In this experiment the levels of triglycerides, total cholesterol, cholesterol of nonhigh-density lipoproteins, low-density and very low-density lipoproteins, as well as the cholesterol and protein content of high-density lipoproteins normalized. The low fat food did not cause glycosylation reactions regression. With the administration of nettle, burdock extracts or metformin to animals that continued to receive high fat food the blood glucose, triglycerides, total cholesterol, cholesterol of nonhigh-density lipoproteins, low-density and very low-density lipoproteins levels decreased by l.6­7.l fold as compared to the parameters in streptozotocine diabetes mellitus. Cholesterol and protein content of high-density lipoproteins increased by l.4­3.7 fold. The herbal extracts also prevented malonic dialdehyde formation, high-density lipoproteins and hemoglobin glycosylation. The nettle and burdock extracts more effectively decreased hyperglycemia, hypertriglyceridemia and lipoperoxidation in animals fed with low fat food. Metformin in the experiment with low fat intake decreased the glucose, low-density and very low-density lipoproteins content to a maximal degree and prevented high-density lipoproteins glycosylation.
[Mh] Termos MeSH primário: Arctium/química
Diabetes Mellitus Experimental
Dislipidemias
Extratos Vegetais/farmacologia
Urtica dioica/química
[Mh] Termos MeSH secundário: Animais
Glicemia/metabolismo
Diabetes Mellitus Experimental/sangue
Diabetes Mellitus Experimental/tratamento farmacológico
Dislipidemias/sangue
Dislipidemias/tratamento farmacológico
Hemoglobina A Glicada/metabolismo
Masculino
Malondialdeído/sangue
Camundongos
Extratos Vegetais/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Blood Glucose); 0 (Glycated Hemoglobin A); 0 (Plant Extracts); 4Y8F71G49Q (Malondialdehyde)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180216
[Lr] Data última revisão:
180216
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180130
[St] Status:MEDLINE


  8 / 8896 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29327896
[Au] Autor:Petrovic G; Bjelakovic G; Benedeto-Stojanov D; Nagorni A; Brzacki V; Markovic-Zivkovic B
[Ti] Título:Obesity and metabolic syndrome as risk factors for the development of non-alcoholic fatty liver disease as diagnosed by ultrasound.
[So] Source:Vojnosanit Pregl;73(10):910-20, 2016 Oct.
[Is] ISSN:0042-8450
[Cp] País de publicação:Serbia
[La] Idioma:eng
[Ab] Resumo:Introduction/Aim: Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease of a broad histological spectrum, characterized by the accumulation of triglycerides in more than 5% of hepatocytes in the absence of consuming alcohol in quantities harmful to the liver. The aim of our study was to determine the importance of anthropometric and laboratory parameters as well as metabolic syndrome (MS) for the diagnosis of NAFLD and to estimate their influence on the degree of liver steatosis as evaluated by ultrasound (US). Methods: The study included 86 participants, 55 of whom had fatty liver diagnosed by ultrasound and they comprised the study group. The control group consisted of 31 control subjects. During the course of hospitalization at the Clinic of Gastroenterology and Hepatology, Clinical Centre Nis, the patients had their anamnesis taken, and anthropometric measurements as well as biochemical blood analyses and abdominal ultrasound were performed. Results: The patients with NAFLD had statistically higher values of body mass index (BMI), waist circumference (WC), systolic (SBP) and diastolic blood pressure (DBP), levels of alanin and aspartate aminotransferase (ALT, AST), gamma-glutamyl transpeptidase (GGT) (p<0.001), low-density lipoprotein cholesterole (LDL), total bilirubin (TBIL) (p<0.05), total cholesterol (p<0.01), triglycerides (TGL), urates, C-reactive protein (CRP), ferritin, fibrinogenes, fasting blood glucose (FBG), insulin and Homeostasis Model Assessment (HOMA-IR) (p<0.001), whereas the levels of high-density lipoprotein cholesterol (HDL) were higher in the control group (p<0.05). In the NAFLD group, there were statistically significantly more patients with hypertension (72.73% vs. 12.90%, p<0.001) and type 2 diabetes mellitus (DM) (47.27%). Metabolic syndrome was determined in 48 (87.27%) patients of the study group. An equal number of patients, 16 of them (29.09%), had 3, 4 and 5 components of MS. In the NAFLD group there were 17 overweight (30.91%) (BMI from 25 kg/m2 to 29.9 kg/m2) and 38 (69.09%) obese patients. (BMI ≥ 30.0 kg/m2). The largest number of patients in the obesity group, 22 (40.00%) of them, had the first degree obesity (BMI from 30 kg/m2 to 34.99 kg/m2). The largest number of the NAFLD group patients - 23 (41.82%), had an ultrasound finding of grade 3 fatty liver, 20 patients (36.36%) had grade 2 and 12 (21.82%) grade 1 fatty liver. Kruskal-Wallis test and ANOVA analysis showed statistically significant differences between groups with different US grade for insulin, LDL-cholesterol, WC, BMI (p<0.05), as well as HOMA-IR and body weight (BW) (p<0.01). Metabolic syndrome was statistically more present in patients with US finding grades 2 and 3 (p<0.01) in relation to grade 1 US finding, as well as obesity, hypertension and DM type 2 (p<0.05). Conclusion: The results of our study have confirmed that a high percentage of patients with high risk factors (DM, MS, dyslipidemia, hypertension) have NAFLD.
[Mh] Termos MeSH primário: Síndrome Metabólica/epidemiologia
Hepatopatia Gordurosa não Alcoólica/diagnóstico por imagem
Hepatopatia Gordurosa não Alcoólica/epidemiologia
Obesidade/epidemiologia
Ultrassonografia
[Mh] Termos MeSH secundário: Adulto
Biomarcadores/sangue
Pressão Sanguínea
Índice de Massa Corporal
Estudos de Casos e Controles
Diabetes Mellitus/diagnóstico
Diabetes Mellitus/epidemiologia
Dislipidemias/sangue
Dislipidemias/diagnóstico
Dislipidemias/epidemiologia
Feminino
Seres Humanos
Hipertensão/diagnóstico
Hipertensão/epidemiologia
Hipertensão/fisiopatologia
Masculino
Síndrome Metabólica/sangue
Síndrome Metabólica/diagnóstico
Síndrome Metabólica/fisiopatologia
Meia-Idade
Hepatopatia Gordurosa não Alcoólica/sangue
Obesidade/sangue
Obesidade/diagnóstico
Obesidade/fisiopatologia
Valor Preditivo dos Testes
Prevalência
Estudos Prospectivos
Fatores de Risco
Sérvia/epidemiologia
Índice de Gravidade de Doença
Circunferência da Cintura
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180213
[Lr] Data última revisão:
180213
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180113
[St] Status:MEDLINE
[do] DOI:10.2298/VSP150514093P


  9 / 8896 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29325849
[Au] Autor:Patel V; Joharapurkar A; Kshirsagar S; Sutariya B; Patel M; Pandey D; Patel H; Ranvir R; Kadam S; Patel D; Bahekar R; Jain M
[Ad] Endereço:Zydus Research Centre, Cadila Healthcare Limited, Sarkhej-Bavla N.H.No.8A, Moraiya, Ahmedabad, 382210, India.
[Ti] Título:Coagonist of GLP-1 and glucagon decreases liver inflammation and atherosclerosis in dyslipidemic condition.
[So] Source:Chem Biol Interact;282:13-21, 2018 Feb 25.
[Is] ISSN:1872-7786
[Cp] País de publicação:Ireland
[La] Idioma:eng
[Ab] Resumo:Dyslipidemia enhances progression of atherosclerosis. Coagonist of GLP-1 and glucagon are under clinical investigation for the treatment of obesity and diabetes. Earlier, we have observed that coagonist reduced circulating and hepatic lipids, independent of its anorexic effects. Here, we investigated the role of coagonist of GLP-1 and glucagon receptors in complications of diet-induced dyslipidemia in hamsters and humanized double transgenic mice. Hamsters fed on high fat high cholesterol diet were treated for 8 weeks with coagonist of GLP-1 and glucagon receptors (75 and 150 µg/kg). Pair-fed control was maintained. Cholesterol fed transgenic mice overexpressing hApoB100 and hCETP with coagonist (300 µg/kg) for 4 weeks. After the completion of treatment, biochemical estimations were done. Coagonist treatment reduced triglycerides in plasma, liver and aorta, plasma cholesterol and hepatic triglyceride secretion rate. Expressions of HMG-CoA reductase and SBREBP-1C were reduced and expressions of LDLR, CYP7A1, ABCA1 and ABCB11 were increased in liver, due to coagonist treatment. Coagonist treatment increased bile flow rate and biliary cholesterol excretion. IL-6 and TNF-α were reduced in plasma and expression of TNF-α, MCP-1, MMP-9 and TIMP-1 decreased in liver. Treatment with coagonist reduced oxidative stress in liver and aorta. Energy expenditure was increased and respiratory quotient was reduced by coagonist treatment. These changes were correlated with reduced hepatic inflammation and lipids in liver and aorta in coagonist treated hamsters. Coagonist treatment also reduced lipids in cholesterol-fed transgenic mice. These changes were independent of glycaemia and anorexia observed after coagonist treatment. Long term treatment with coagonist of GLP-1 and glucagon receptor ameliorated diet-induced dyslipidemia and atherosclerosis by regulating bile homeostasis, liver inflammation and energy expenditure.
[Mh] Termos MeSH primário: Aterosclerose/metabolismo
Dislipidemias/metabolismo
Peptídeo 1 Semelhante ao Glucagon/metabolismo
Glucagon/metabolismo
Inflamação/metabolismo
Fígado/metabolismo
[Mh] Termos MeSH secundário: Animais
Aterosclerose/patologia
Colesterol/metabolismo
Cricetinae
Dislipidemias/patologia
Inflamação/patologia
Metabolismo dos Lipídeos/fisiologia
Fígado/patologia
Masculino
Camundongos
Camundongos Transgênicos
Receptores de Glucagon/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Receptors, Glucagon); 89750-14-1 (Glucagon-Like Peptide 1); 9007-92-5 (Glucagon); 97C5T2UQ7J (Cholesterol)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180209
[Lr] Data última revisão:
180209
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180113
[St] Status:MEDLINE


  10 / 8896 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29320547
[Au] Autor:Augustemak de Lima LR; Petroski EL; Moreno YMF; Silva DAS; Trindade EBMS; Carvalho AP; Back IC
[Ad] Endereço:Research Centre for Kinanthropometry and Human Performance. Department of Physical Education. Federal University of Santa Catarina. Florianópolis, Santa Catarina, Brazil.
[Ti] Título:Dyslipidemia, chronic inflammation, and subclinical atherosclerosis in children and adolescents infected with HIV: The PositHIVe Health Study.
[So] Source:PLoS One;13(1):e0190785, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:HIV-infected children and adolescents may be at risk for cardiovascular disease due to chronic inflammation and exacerbation of risk factors. The aim of this study was as follows: 1) compare cardiovascular risk factors, chronic inflammation, and carotid intima-media thickness (IMTc) between the HIV and control groups; 2) determine the association of HIV and antiretroviral (ART) regimens with cardiovascular risk factors, chronic inflammation, and IMTc; and 3) identify variables associated with elevated IMTc. Cross-sectional analysis of 130 children and adolescents, 8-15 years of age, divided into HIV-infected (n = 65) and healthy control (n = 65) participants. Body fat, blood pressure, glycemia, insulin, and glycated hemoglobin, total cholesterol and fractions (LDL-C and HDL-C), triglycerides, C-reactive protein (CRP), interleukin (IL)-6, tumor necrosis factor-alpha (TNF-α), and the IMTc were measured. The results showed HIV-infected children and adolescents had higher levels of glycemia (87.9 vs. 75.9 mg.dL-1, p< 0.001), LDL-c (94.7 vs. 79.5 mg.dL-1, p = 0.010), triglycerides (101.2 vs. 61.6 mg.dL-1, p< 0.001), CRP (1.6 vs. 1.0 mg.L-1, p = 0.007), IL-6 (1.42 vs. 0.01 pg.mL-1, p< 0.001), TNF-α (0.49 vs. 0.01 pg.mL-1, p< 0.001), mean IMTc (0.526 vs. 0.499 mm, p = 0.009), and lower HDL-c (53.7 vs. 69.4 mg.dL-1, p< 0.001) compared to controls. Systolic blood pressure (ß = 0.006, p = 0.004) and TNF-α (ß = -0.033, p = 0.029) accounted for 16% of IMTc variability in HIV-infected children and adolescents. In patients using protease inhibitors-based ART, male gender (ß = -0.186, p = 0.008), trunk body fat (ß = -0.011, p = 0.006), glucose (ß = 0.005, p = 0.046), and IL-6 (ß = 0.017, p = 0.039) accounted for 28% of IMTc variability. HIV-infected children and adolescents may be at risk for premature atherosclerosis due to chronic inflammation and dyslipidemia. Interventions with the potential to improve lipid profile, mitigate inflammation, and reduce cardiovascular risk are needed.
[Mh] Termos MeSH primário: Aterosclerose/complicações
Dislipidemias/complicações
Infecções por HIV/complicações
Inflamação/complicações
[Mh] Termos MeSH secundário: Adiposidade
Adolescente
Antirretrovirais/uso terapêutico
Aterosclerose/diagnóstico por imagem
Aterosclerose/epidemiologia
Aterosclerose/fisiopatologia
Biomarcadores/sangue
Glicemia
Espessura Intima-Media Carotídea
Criança
Estudos Transversais
Dislipidemias/diagnóstico por imagem
Dislipidemias/epidemiologia
Dislipidemias/fisiopatologia
Feminino
Infecções por HIV/diagnóstico por imagem
Infecções por HIV/tratamento farmacológico
Infecções por HIV/fisiopatologia
Seres Humanos
Inflamação/diagnóstico por imagem
Inflamação/epidemiologia
Inflamação/fisiopatologia
Interleucina-6/sangue
Lipídeos/sangue
Masculino
Inibidores de Proteases/uso terapêutico
Fatores de Risco
Fatores Sexuais
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Anti-Retroviral Agents); 0 (Biomarkers); 0 (Blood Glucose); 0 (IL6 protein, human); 0 (Interleukin-6); 0 (Lipids); 0 (Protease Inhibitors)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180205
[Lr] Data última revisão:
180205
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180111
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0190785



página 1 de 890 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde